Valeria Povolotsky, Director, Global Business Development, Roche Partnering, Roche, Nutley, NJ, US.

Dr Povolotsky is an expert in Biotech/Pharma Licensing & Investment with over 20 years experience in R&D and Global Business Development. With a strong background in science, (Master in Biochemistry and PhD in Pharmacology), Dr Povolotsky spent over 12 years in the drug development from preclinical research, clinical and regulatory, then moving to Business Development for the last 10 years, focusing on the Venture investments (Magellan Summit), Scientific Intelligence (Daiichi-Sankyo), and Partnering (Roche). Dr Povolotsky is currently responsible for finding innovations and potential opportunities for collaboration in the Emerging Markets.

Roche: New Ways of Creative Partnership

Starting from March 1st 2010, Roche Partnering has launched new Partnering program (Helios), which is entirely dedicated to the the Emerging Markets, and which has strong focus on the Eastern Europe. The major purpose of this program is to find innovations and to build creative partnerships to develop new drugs, and to make difference in patient’s lives.

Prof. Florian Wurm , CSO
ExcellGene SA

Florian Wurm is a Biologist/Molecular Geneticist (University of Giessen, Germany) by training. He worked in industry (Behringwerke, Marburg and Genentech, San Francisco) for 15 years during the earlier parts of his career and has spend 2 years at Harvard University, Boston. In 1995 he was appointed Professor for Biotechnology at EPFL (Lausanne). In 2002 he started ExcellGene SA, Monthey, Switzerland. Florian holds the position of CSO and interim CEO at this company. Florian is member and past Chairman of the European Society of Animal Cell Technology. He has published more than 180 papers and holds more than 20 patents on protein expression in cultivated mammalian cells. During his career he has contributed to the generation of a number of high profile protein therapeutics which are sold today as "block-buster" products of the biopharmaceutical industry. 

 Producing proteins in bioreactors with mammalian cells: From mgs to kgs, from academia to industry - a 25 year perspective. 

Antibodies,  antibody-fusion proteins and other high-value proteins are produced now in kg to ton quantities for the treatment of a small number of diseases, benefiting hundreds of thousands of affected patients. The unprecedented medical and commercial success of these molecules (sales of over 50 Billion US $/year)  has raised enormous interest in the biopharmaceutical research community, resulting in hundreds of new molecules to be explored for the same or other diseases.  A major bottleneck for bringing such promising protein candidates for treatment into the clinical setting is the amount of time and money required to manufacture even gram quantities of these under appropriate conditions with reproducible yield and high quality. Mammalian cells in bioreactors have been used and optimized over the last 25 years to produce these proteins with ever increasing yields. Today, gram/liter quantities of such proteins can be made in reactors of up to 20'000 Liter volume. However, each molecule is a new challenge and requires profound development efforts to obtain such highly productive production processes. The knowledge for such process development and establishment of manufacturing capacity is in the hands of few leading companies. The talk will cover the evolution of insights and processes during the last 2 decades and will also provide a view on the future in process sciences and manufacturing of antibodies and other recombinant antibodies made in mammalian cells in bioreactors. An emphasis will be given on fast, efficient and new production principles, such as large scale transient gene expression and the use of single use, disposable bioreactor systems. All of these are able to cut cost and to reduce time for moving a new expression vector to the reality of sufficient quantity of product for preclinical and clinical research, as well as for manufacturing for the market. 

Frank Sehlmeyer, Head of Business Development Group
Fermentas UAB

Frank is already more than 14 years with Fermentas.  While starting already during his PhD to work in sales, after his PhD in molecular biology (chemistry) he held several leading positions in sales, marketing and technical support.
He was involved in establishing the organization in the Benelux, Austria, Scandinavia and the UK and developed the Fermentas freezer program as well as several products.In 2007 he moved from the sales and marketing affiliate in Germany to Lithuania where in Vilnius the Fermentas R&D and production site is located.Currently he is heading the business development group and responsible for Fermentas’ bulk, OEM & customized solutions business as well as licensing.

Solutions for success made in Lithuania

Fermentas is a perfect example for showing how listening to customers and steadily striving for improvements and professionalism is leading to mutual success and leadership in the industry. During the last 30 years Fermentas customers and people were driving an unknown spin-out of the Vilnius University to a well recognized multi-national in the life sciences business.

Starting with a few me-too products produced in and for university labs, Fermentas is now an ISO and GMP certified provider of more than 1000 solutions and known as a reliable partner for the research community and the molecular diagnostics and pharmaceutical industries.

Discover how solutions for success are made in Lithuania: Identifying needs while listening to our partners; developing solutions employing know-how and innovative technologies; producing in certified clean rooms ensuring highest quality and performance; thus delivering value-added solutions for mutual success.

Overview of biotechnology potential in CE

Dr. Martin Buncek, member

Overview of Czech Biotech 

More than a decade ago it would had been hard to find any biotech companies in the Eastern Europe. But the industry support and talented groups of English-speaking researchers who usually work for a far less than their colleagues in the UK, US or even in Germany started a new era of biotechnology in the Czech Republic. Even the cutting-edge molecular biotechnologies are still lagging behind the long tradition in classical biotechnologies, the investments into the infrastructure, of which the large portion is going into the biotech sector, is a fuelling environment for the biotech success. Together with a government measures, like tax breaks for investors, research subsidies and help with training, it aims at sparking a biotech revolution in the Czech Republic. Evidenced by the recent foundation of the Association of the Czech biotech companies, the CzechBio, the biotech revolution has started.

Monika Jankovics, project manager

Hungarian Biotechnology Association

Monika Jankovics is a Project Manager at the Hungarian Biotechnology Association. She received her Diploma (M.Sc.) in English Language and Literature in 2005 at the University of Szeged. Her current tasks are preparation and management of national and international grant proposals and projects, organizing various events and conferences, administration, communication and coordination of matters involving the interest of the Association.

Overview of the Biotechnology Sector in Hungary

The Biotechnology Report: “Biotech in the New EU Member States: An Emerging Sector” prepared by EuropaBio and Venture valuation in 2009 ranks Hungary with the highest DCI (Development Capacity Index –a tool for the assessment and comparison of the biotechnology development status and potential of a country at a certain point in time, based on available data).

In their presentation the Hungarian Biotechnology Association will give a general overview of the Hungarian biotechnology industry including among others the major sectors, areas of activity, R&D and investment outlook, highlighting the business climate, regulations and policies. The lecture will illustrate, using comparative tools, the position occupied by the country on the international biotech market. Last but not the least it will pinpoint the key factors that provide the basis for Hungary becoming one of the leading countries in biotechnology in the Central Europe region.

Prof. Leonas Grinius, representative
Lithuanian Biotechnology association

 2006 – Current - Consultant in Biomedicine & Biotechnology, Institute of Biotechnology/Lithuanian Biotechnology Association, Vilnius, Lithuania
2005-2006 - Vice-President, Marketing, Fermentas Life Sciences, Vilnius, Lithuania
2003-2005 - Scientist, Cincinnati Children’s Hospital Research Foundation, Cincinnati, USA

Opportunities for Lithuanian Biotech Related to Participation in the EU Baltic Sea Flagship project “Health Region”

The EU Baltic Sea Flagship project “Baltic Sea Health Region” has now been launched within the framework of the recently announced EU Strategy for the Baltic Sea. The mission of the project is to advance quality of life of the citizens living in the Baltic Sea Region, promote sustainable regional economic development and foster eco-friendly innovation. 

The mission of the project is to advance quality of life of the citizens living in Scandinavia and Baltic Sea Region, promote sustainable regional economic development and foster eco-friendly innovation.

A task force composed of the Lithuanian Biotechnology Association (mandated by the Lithuanian Government), BioCon Valley (mandated by Landesregierung Mecklenburg-Vorpommern), ScanBalt (representing ScanBalt BioRegion) and ScanBalt Academy (representing the highlight of research in ScanBalt BioRegion) has identified the following focus areas:

• Innovation & Cooperation (exploit competencies and overcome challenges by joining forces) 
• Healthy ageing (tackle demographic development and ensure better life)
• Prevention (promote awareness and level regional differences in life expectancies)
• E-Health (deliver health care everywhere and exploit regional spearhead competencies)
• Financing (identify and develop models, promote a Baltic Sea Region Fund or network for research, innovation and education)
• Strategic communication

Unique challenges and opportunities for the Lithuanian biotech related to participation in implementation of the EU Baltic sea strategy will be analysed in this presentation and conclusions will be drawn that are relevant for development of Health Economy in Scandinavia and Baltic Sea Region.

Prof.Tadeusz Pietrucha, CEO

Bio-Tech Consulting Sp zoo

Tadeusz is a manager of Bio-Tech Consulting since 1996. He combines this activity with heading Lodz University’s research team of Medical Biotechnology for five years now. He graduated at Lodz University in Biology, did his PhD at Medical University of Lodz and carried his post-doctoral training at University of Notre Dame. He is an author and a co-author of more than 40 scientific experimental papers, 12 research overviews, as well as reviews on biotechnology.

 Tadeusz  was one of the first graduates of the postgraduate studies Master of Science in Science and Technology Commercialization carried at Lodz University, Management Faculty, on the license of the University of Texas in Austin. Tadeusz complemented his education with postgraduate studies at Warsaw School of Economics in Strategic Planning of Enterprises Developmental Activity.

He is a co-founder and vice-CEO of biotech company Mabion. Tadeusz cooperates with seed-capital funds specializing in financing of R&D projects in biotechnology.

Juris Vanags, chairman of the board
Latvian Biotechnology Association

Juris Vanags graduated from the University of Latvia as an engineer of physics (1983) and got a PhD in Bioengineering in 1993. Presently he is a Managing Director of JSC, Biotehniskais centrs (manufacturer of bioreactors); Chairman of board of Latvian Biotechnology Association and associate professor of Riga Technical University (bioprocess engineering).

The overview of Biotechnology in Latvia

Association of Biotechnology of Latvia (ABL) was created as the first Latvian biotech network in 2006. The country’s long experience and traditions, the availability of highly qualified specialists, cost efficiency, high competence in R&D and a developing manufacturing base are the factors that form an excellent foundation for business and innovative activities in Latvia’s biotech sector.

The main aim of the ABL is to promote the development of biotechnology in Latvia by clustering of academia, governmental bodies and industry in joint projects, by participation in the international projects, by joint representation of their members in meetings and exhibitions, by promoting of education of young specialist in biotechnology and related fields, and by rising of public awareness on biotechnology in the society.

Dr Oleh V. Stasyk, deputy director for science
Institute of Cell biology, National Academy of Sciences of Ukraine

Dr. Oleh Stasyk, Senior scientist, Deputy director for science, Head of Department of Cell Signaling, Institute of Cell Biology, National Academy of Sciences of Ukraine (ICB), Lviv.

Research at ICB encompasses a broad range of modern biological disciplines such as cell and molecular biology, cancer research, microbiology, biochemistry, genetics, Immunology and biotechnology. ICB has a dynamic research environment, skilled personnel and well equipped laboratories. Over the last 5 years, ICB scientists have published more than 70 articles in many highly ranked international journals, obtained 5 Ukrainian patents and 7 international patents. ICB has been successful in obtaining grants from many international sources, including the STCU, INTAS, CRDF, FIRCA, NATO, National Cancer Institute (USA) and the Swedish Academy of Sciences. The Institute has extensive and successful international collaboration. ICB was the main organizer of several prestigious international scientific conferences. Director of ICB Prof. Andriy Sibirny is currently the Chair of International Commission on Yeasts, the prestigious international scientific organization. ICB is a recognized leader in Ukrainian biological science in the field of molecular genetics and biotechnology of industrially-important yeasts used for the production of vitamins, recombinant proteins for medicine, agriculture, and development of novel biotechnologies. Among yeast biotechnologies and products developed at ICB are: one of the best world yeast producers of vitamin B2 (riboflavin), recombinant enzymes of arginine degradation as anticancer agents, cell- and yeast enzyme-based biosensors and analytical kits for important compounds, novel technologies of biofuel ethanol production from plant material using genetically-engineered strains of non-conventional yeasts.

Biotechnology in Ukraine: current state and future challenges

Biotechnology in Ukraine is still in an incubation phase but bears high potential for vigorous development. As a big Eastern European country, Ukraine is not only a sizable market for biotech products and services but also a source of new technologies, many still to be exploited, and in urgent need of reforming its biotech sector. The goals that have to be set is to overcome the limitations of post-soviet economical model that did not incorporate efficient technology transfer system between research institutes and businesses, make scientific research more business-oriented, create supportive environment for small companies developing new innovative biotechnologies, fully exploit potential of modern biotechnologies for the development of Ukrainian agricultural sector and modernization of health care system, become integrated into European biotechnological sphere more active in international collaboration. Recently new initiatives emerged in Ukraine aimed at establishing an efficient domestic technology transfer system, science and technology parks with strong biotech component, business incubators. One example is Lviv open innovation system that is being built with full support of the city authorities, local businesses and research institutions. It has to be emphasized that European experience, especially that of new EU members as Poland, Baltic states is of tremendous importance for reforming Ukrainian biotechnology sector.

Prof.Rodica-Mariana Ion
National Institute of Research and Development for Chemistry and Petrochemistry, Bucharest

 Date of birth: 07^th November, 1958

Nationality: Romanian
Education and qualifications: B. Sc. in Chemistry, Masters in physics, Ph. D. in chemical science, Post-Doc in  Management and quality system.

Professional positions: President of  Scientific Council, ICECHIM, Bucharest; Vice-President of Management Board at ICECHIM, Bucharest; Professor, Department of Materials Engineering, Valahia, Targoviste, Romania; Ph.D.Supervisor at Valahia University of Targoviste

International co-operations:  FP6 – DEVELONUTRI Project, 2007-2010; Management Committees of EU Actions: COST D8 (2001), D18(2001-2006) and D20 (2004-2007), Principal Coordinator at WG 0012/02 of COST D20, Experts of INTAS, Programmes.

Patents : in chemistry and medicine

Awards and honors: Gold Medal – Romanian Award from the Research Ministry for the Project CEEX 18/2005, Health area, 2008; Gold Medal EUREKA Innova Brussels, 2008; Prize of Rudy Demotte, Minister President of the Walloon Government – EUREKA Innova Brussels, 2008; Gold medal with Congratulations of Jury for a patent request, Geneva, 37^th Salon of Inventions, 2009; Special prize of Russian Ministry of Science and Education for a patent request, Geneve, 2009; Special Prize “New Times”, Moscow, 2009; Gold Medal at Innovation and Invention Salon, Moscow, 2009.

 Nano- and bio-technologies in therapeutics and environment bioengineering - romanian experience

The talk is framed from the perspective of the Nano-Biotechnology as a new Romanian strategic solution with significant sustainability advantages:medical biotechnology as red biotechnology and agri-food biotechnology as
green biotechnology. Will be described how the combination between Biotechnology, Green chemistry and Nanomaterials is one the main source for Romanian radical innovations of new products and markets. Also, the implications of Nano in Bio -> Medicine (including biomolecules for efficient new medical treatments and diagnosis), and in Environment -> Responsibility (with risk assessment and risk reduction), will be treated.

  Biotechnologies - from bench to market  

Dr. Kata Mazalin, General Manager

Assign Group/GM Assign Hungary Kft.

Born in Hungary but living in Austria since 1995 Kata graduated from Vienna Medical University in 2002 and started to work in the pharmaceutical industry immediately afterwards. Starting to gain experience at an Austrian CRO she worked herself through all fields of clinical research, from medical writing, planning and development of clinical studies, global project management and biostatistics. Kata joined Assign Clinical Research in 2005 and in 2006 the Hungarian office has been opened, which she manages since then. Kata has a strong background and years of experience in oncology and in the last years she extended her expert knowledge in biotech research. Currently she is living and working both in Vienna and Budapest.

Jerzy Pieczykolan, Project Manager
Adamed Sp. z o.o.

Jerzy Pieczykolan is a Project Manager at Adamed Sp. z o.o. with overall management responsibility for research and development of two innovative oncology projects. Jerzy graduated with honors from the Faculty of Mathematics and Natural Sciences of Catholic University of Lublin, specializing in biotechnology and molecular biology.

Biotechnologies - different ways to achieve success
New therapies -choosing the right strategy of development

- Biotech today - progress in biotech development
- New technologies for speeding up the development process
- Examples of pitfalls and opportunities during development process
- Models of cooperation in development process
- Outsourcing as a general model of cooperation
- Licensing - is it still a chance for faster development?
- CMO companies - how can they be helpful

Fund rising for  biotech enterprises



Oliver Murphy, Partner, Financial Advisory Services
Deloitte

Oliver is a graduate of the University of Manchester in Economics and Government. He speaks fluent Polish. Oliver has 9 years experience of transaction support and due diligence in Poland and in total has been involved in more than 300 transactions in a wide variety of industries. 
Oliver has has a wide range of corporate finance, due diligence and restructuring and integration experience within both the UK and Poland.
Oliver specialises in cross-border transaction support engagements comprising large multi-disciplinary, multinational teams. 

 
Magdalena Jabłońska, Manager in Deloitte Grants & Incentives Team
Deloitte


She has many years of various and universal  experience in obtaining EU grants from public sources.  
She has advised companies during the operation of the PHARE program, through the funds available in 2004-2006 including  Norwegian Financial Mechanism and EEA Financial Mechanism, until the funds available at the present time from EU financial perspective 2007-2013. Additionally, she was responsible for financial engineering of investment (preferential loans, tax exclusion, subsidies for new employments). Currently she manages a large number of various and complex projects as regards applying for EU or domestic funds. 
Magdalena specializes in obtaining public aid for innovative investments in production and service sector, R&D projects and training funds for enterprises. She was a team member and also coordinator of works aimed at preparation of application documentation in dozens of projects applying for financial aid. Among her projects are investments for large, medium and small companies from both production, as well as service sectors.
Magdalena organizes numerous trainings and lectures for enterprises regarding funding opportunities with reference to EU funds. She is an author of numerous articles about public aid in professional press as well as is coauthor of publication prepared for Ministry of Regional Development in cooperation with KPP Lewiatan – “Entrepreneur’s Map 2007-2013” and prepared with KPP “Innovative funds for innovative investments”.

Methods of financing operations and development in the pharmaceutical and biotechnology sectors

•    Planning of the undertaking as key element of obtaining financing 
•    Optimum models of linking private and public funding 
•    Case studies – analysis of typical projects and their financing. 
 

Grzegorz Gromada, CEO
MCI Bioventures

Grzegorz Gromada - Investment Partner MCI Management SA, odpowiedzialny za zarządzanie funduszem MCI.BioVentures FIZ i rozwój portfrela funduszy z obszaru biotechnologii i lifescience.Od 2007 r. Prezes Zarządu MCI.BioVentures Sp. z o.o.
Wcześniej, od 1995 do 2007 r., zastępca dyrektora Wrocławskiego Centrum Transferu Technologii Politechniki Wrocławskiej; od 1998 r. do 2007 r. - wiceprezes zarządu Wrocławskiego Parku Technologicznego SA. W 2000 r. pełnił rolę Polskiego Oficera Łącznikowego z Komisją Europejską d.s. udziału małych i średnich przedsiębiorstw w Piątym Programie Ramowym Badań i Rozwoju Technologicznego Wspólnoty Europejskiej. Koordynował pracę Ośrodka Przekazu Innowacji IRC w Polsce zachodniej oraz był uczestnikiem Advisory Group europejskiej sieci Innovation Relay Centres. Członek Grupy Zarządzającej projektu Regionalna Strategia Innowacji dla Dolnego Śląska. Autor ekspertyz z zakresu wyceny transferu know-how dla Ministerstwa Gospodarki. Wiceprezes Zarządu Stowarzyszenia Organizatorów Ośrodków Innowacji i Przedsiębiorczości w Polsce.

Financing of biotech start-ups by the venture capital fund MCI.BioVentures 
US and European venture capital funds have developed a set of criteria that enhance success of biotech start-ups. These criteria will be presented taking into account more than ten years of investment experience of MCI. The characteristics of a biotech investments and a risk profile associated with such investments will be discussed. Presentation will contain the example of the MCI.BioVentures investment in the Genomed company founded in Warsaw, in year 2007 by group of scientist. Genomed is the leader in DNA sequencing and synthesis, and molecular diagnostics in Poland.


Artur Chabowski, CEO
ACADIA Artur Chabowski S.K.A.

Financial adviser, with over 15 years experience in investment banking, specializing in mergers and acquisitions in Central and Eastern Europe. He has been working for the Ministry of Privatization, CAIB Financial Advisers, ABN AMRO and KPMG. Since 2004, an independent financial adviser and private equity investor. Owner of ACADIA S.K.A, an Authorized Adviser at New Connect on Warsaw Stock Exchange. He graduated from Warsaw University of Technology, and done his postgraduate studies at Woodrow Wilson School of Public and International Affairs at Princeton University.

Fund rising for biotech industry on New Connect – Mabion case study
Are Polish financial institutions ready to finance biotech projects? What are their main concerns? What is the opinion about the biotech industry among individual investors? Is New Connect a good place to seek financing for biotech  projects? How New Connect investors value a biotech projects in Poland? How much financing you can obtain on New Connect? Is Mabion a good example for other biotech companies to follow? 





Management of biotech enterprises


Julie Kjestrup, Healthcare Biotechnology Manager
EuropaBio

Julie Kjestrup is Healthcare Biotech Manager at EuropaBio, the European Association for Bioindustries, and is also jointly responsible for the co-ordination of the SME Platform, as well as the National Associations Council, which regroups 26 national associations from all over Europe. A ‘true European’, Julie has two degrees in European studies (from the Universities of Southampton and Sussex, both UK) and has lived and worked/studied in 6 European countries as well as the US. She came to EuropaBio from a position in Government Affairs at GlaxoSmithKline’s Brussels office. Before that, she was in the Press & Public Diplomacy office at the EU Delegation to the US in Washington, D.C.

Creating the right environment for biotech start-ups and SMEs: structures to support innovation and collaboration
Micro, small and medium sized enterprises (SMEs) in the biotech industry represent a great potential for the European economy as a source of innovation, creativity and international competitiveness. However, because of the special characteristics of the sector and difficulties resulting from the recent crisis, SMEs face challenges that need to be addressed with special funding instruments and policy initiatives. In her presentation, beside addressing the above issues, Julie Kjestrup also introduces EuropaBio’s SME Platform which was created to develop and promote recommendations to improve the financial and institutional environment for biotech SMEs.



Paweł Przewięźlikowski, CEO
Selvita


Paweł Przewięźlikowski, the founder and Chief Executive Officer of Selvita, was previously a Vice President of ComArch SA, the largest IT company in Poland. He managed one of the sectors of the firm and oversaw its research and development activities. Mr. Przewięźlikowski started as a systems analyst in 1994 and in 1996 -2007 he was a member of board of the company. Most recently he managed 800+ people at Finance and Services sector of ComArch comprising financial services, retail and FMCG markets. He is a founding partner and the first CEO of Interia.pl, one of the largest Internet portals in Poland. 
Currently Mr. Przewieęźlikowski manages the research commercialization department of Selvita. He holds MSc in information technology from AGH University of Technology in Krakow (Poland) and an MBA from the University of Teesside (UK).

Managing a biotech company in the emerging Krakow cluster – Selvita experiences
Most experts agree that the best place to develop a biotechnology company is in an established life science cluster. But every cluster has to start and the recent examples in Eastern Europe and in Asia prove that it is possible to create a productive environment for life science companies within 10 years from the initial concepts. Selvita is a member of the emerging Krakow commercial biotechnology sector and together with the other companies and institutions from the region has developed an innovative strategy to take advantage both of the long tradition of biomedical research in the city as well as many opportunities and incentives that are available exactly here and now. We use this strategy to build a company capable of helping pharmaceutical companies with bringing innovative, better therapeutics to the market faster and more cost-effectively.
 


 R&D deals in biotech

 Patricia Barclay, Bonaccord Ecosse Ltd

Patricia Barclay studied law at Edinburgh and Oxford Universities before embarking on a career primarily in life sciences which has taken her all over the world.  She held a number of senior positions with Pfizer before becoming General Counsel of Vernalis, a position she subsequently held at the privately  held  multinational Ferring Group and at Solvay Pharmaceuticals.  She has accordingly been involved in decision making at the highest level in very different companies.  She has extensive experience in the negotiation of complex international licensing and cooperation agreements, mergers and acquisitions, the management of intellectual property, public affairs and the establishment and development of internal services and departments.  She has hands on experience of the pharmaceutical, animal health, medical device, chemical, food science and consumer goods sectors.
Patricia is also an accredited mediator.  She is a member of the Association for Conflict Resolution, Mediators Beyond Borders and of the WIPO mediation panel.  She currently serves as chair of the International Bar Association mediation techniques committee for whom she is developing a book of essays.
In 2007 she established Bonaccord, a law firm specialising in the commercialisation of scientific research. While based in Scotland the firm supports clients all over the world. Bonaccord also provides consultancy services to a number of major law firms in life science and related areas.  Additionally, Patricia has developed a number of courses, primarily in intellectual property and entrepreneurship at both practical and academic levels for a variety of institutions including the University of Edinburgh.

Maximising your Return and Enforcing your Rights
This paper will cover two issues of importance to small IP rich companies.  Firstly how by careful structuring of the deal to take into account all aspects of the IP and the overall needs of the company  the benefits to the company can be maximised in both cash and kind and secondly how that company can enforce its contractual rights against a larger and wealthier partner.

 

Biotech companies' issues - deals and support


Dr Mathias Lamparter, Cluster manager
Bio-M, Bavarian Biotech Cluster

2008 to present BioM Biotech Cluster Development GmbH, Cluster Manager for the Bavarian Biotechnology Cluster
2002 - 2007 Ph.D. Student, Institute for Clinical Molecular Biology and Tumor Genetics, Helmholtz Zentrum Munich (German Research Center for Environmental Health) & Institute for Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
1997- 2002 Diploma-Student in Biology, Technical University of Munich

Start-Up Support and Cluster Development in Bavaria
BioM Biotech Cluster Development GmbH serves as the coordinating agency and
management organization of the Munich and Bavarian Biotechnology Cluster, and is central
point of contact for biotech companies in the region. BioM develops new financing concepts
for the biotech industry and provides active assistance and consulting for biotech start-up
companies. As a network organization BioM offers support in marketing, communications as
well as public promotion and aims at optimizing Bavaria's biotechnology positioning on the
international scale through the coordination of R&D co-operations.


Dr Haim V. Levy, INVESTIN Sp. z o.o.

Dr. Levy is an entrepreneur with close to twenty five years involvement in the Bio-Tech space, identifying new business opportunities, nurturing innovation and building businesses. In 2005, Dr. Levy co-founded NanoDerma Ltd. and currently serves as its Chairman. In 1998 he co-founded Be-4 Ltd. and served as CEO and later as Chairman until 2005. Prior to that, Dr. Levy founded Neuromuscular Electrical Stimulation Systems - NESS Ltd. He served as its President and CEO since its inception in 1991 until 1998. NESS was acquired by an American company. During 1987-1990, Dr. Levy served as the Deputy Managing Director of Yeda Research & Development Company Ltd., the technology transfer company of the Weizmann
Institute of Science, one of the world’s leading multidisciplinary research centers. 
In the past seven years Dr. Levy is a practicing attorney in the Hi-Tech domain, specializing, inter alia, in equity investments, licensing and technology transfer transactions.

Practical aspects of licensing transactions between universities, small Biomed companies and healthcare industry.
For universities’ technology transfer entities, as well as for many small and start-up Biomed companies, partnering with a large healthcare company can successfully and effectively bring their innovation through to the market place. This usually works out through a licensing transaction, which is practically a grant of the right to use the intellectual property (IP) in return for royalty. Evaluation of IP is an essential element of any technology transfer process. Furthermore, negotiations for IP licensing require indepth knowledge and experience.
In general, licensing terms are case-specific and vary from transaction to transaction. Each license therefore represents a customized transaction that is structured in accordance to the needs of the particular parties and the technology licensed. Key financial elements of a licensing transaction may include upfront payments, milestone payments and royalties. Oftentimes, the focus of financial negotiations in an IP license is on the percentage royalty rate, but there is much more to the financial terms.


Rafał Witek, Partner,  WTS Patent Attorneys Witek, Sniezko & Partners

Rafał is a partner and co-founder of WTS Patent Attorneys, with a MSc in biotechnology, as well as a Polish and European patent attorney specialising in the protection and commercialisation of inventions in the fields of biotechnology and pharmacy.
He is a consultant for the protection and commercialisation of intellectual property for many public and private scientific organisations in Poland. He advises and aids in the development of several biotechnological companies. Rafał is also a member of the investment commission of the BIB Seed Capital investment fund in Poland.
Rafał is a member of the Polish Chamber of Patent Attorneys and the Institute of European Patent Attorneys, and a board member of the Licensing Executives Society Poland (LES-Poland). He is also a member of AIPPI-Poland.

How to create the IP portfolio and raise the value of the biotechnological start-up company – Read Gene S.A. case study
The goal of this presentation is to demonstrate the fundamental legal questions concerning the creation of a new biotechnological company in Poland and its value creation, using the development of Read Gene S.A. as an example. In particular, we will discuss the most important elements of the patent strategy meant to limit the costs of building the IP portfolio prior to obtaining investors.
WTS Patent Attorneys has partnered with Read Gene S.A. from its inception to its debut on the New Connect exchange, participating in the construction of its legal structure, defining the legal relationship with its parental research institution, as well as the patent protection of the company’s inventions.

Krzysztof Czaplicki, Biotechnology Manager at Science2Business
A graduate of the University of Warmia and Mazury in the Faculty of Biotechnology, completed a postgraduate course in EU pre-accession and structural programmes at the Warsaw School of Economics. He has many years of experience in creating business and in managing the development of companies at various stages of their growth. He excels at strategic management, among other things: at forming and implementing company’s development strategies, creating goodwill, planning and streamlining business processes, as well as at designing and implementing business models. He is an expert in the field of the private sector development; he gained international experience while working for the Private Sector Liaison Officers Network (PSLO Network) to the World Bank Group (WB, IFC, MIGA). A specialist in the area of the assessment of quality and impact on financial results of intangible assets at companies – the methodology of the London School of Economics, the Fraunhofer Institut in Berlin, an expert at the Polish Confederation of Private Employers Lewiatan. A member of expert teams appointed at the Ministry of Science and Higher Education to evaluate projects entered for the following programmes: “Kreator Innowacyjności – wsparcie innowacyjnej przedsiębiorczości akademickiej” [“Creator of Innovativeness – support for innovative academic entrepreneurship”] and “Patent Plus – wsparcie patentowania wynalazków” [“Patent Plus – support for the patenting of inventions”]. He has been associated with the biggest network of business angels ”Lewiatan Business Angels” since the moment of its creation.